| DB ID | MyCo_3194 |
| Title | Interference of confounding factors on the use of (1,3)-beta-D-glucan in the diagnosis of invasive candidiasis in the intensive care unit |
| Year | 2014 |
| PMID | 25217227 |
| Fungal Diseases involved | Invasive candidiasis |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | spp. |
| Organism | Candida spp. |
| Ethical Statement | The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, and was approved by our ethics committees (Prot. PPC 2395). |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Italy |
| Cohort | Patients admitted to the ICU department of University of Verona, Italy, between March 2009 and July 2012 were retro- spectively evaluated (n=2,912). A total of 267 patients were tested during the study period. |
| Cohort No. | 267 |
| Age Group | 61.5 |
| P Value | None |
| Sensitivity | 0.829 |
| Specificity | 0.567 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
